A Phase I, Multicenter, Open-Label, First-in-human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors.
Clinical Cancer Research（2014）
Key words
Tumor Suppression,Cancer Therapy,Hedgehog Signaling
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined